CADI-R504

CADI-R504 is a discovery-stage therapeutic program developed by Bio-Modeling Systems (BMSystems) using its proprietary Computer-Assisted Deductive Integration (CADI™) platform. The program is specifically focused on the "Müllerian regression mechanisms," which are the biological pathways responsible for the regression of Müllerian ducts during embryonic development. In the context of oncology, these mechanisms are of significant therapeutic interest because they can be leveraged to inhibit the growth of Müllerian-derived tumors, such as ovarian, endometrial, and cervical cancers. The program aims to identify and validate novel therapeutic targets and protocols that can trigger regression or apoptosis in these cancer types, primarily by modulating the Anti-Müllerian Hormone (AMH) and Anti-Müllerian Hormone Receptor (AMHR) signaling pathways. BMSystems categorizes CADI-R504 as a "high interest" program within its mechanism-based medicine pipeline.

Other names

CADI-R504-Bio-Modeling Systems-OncologyCADI-R-504-Bio-Modeling Systems-OncologyCADI-R 504-Bio-Modeling Systems-Oncology